Ammonium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate, developed for use as a polymerization processing aid in the manufacture of fluoropolymers, was tested for its potential chronic toxicity and carcinogenicity in a 2-year oral dosing study in Sprague–Dawley rats. Male rats were given daily doses of either 0, 0.1, 1 or 50 mg/kg; females were given either 0, 1, 50 or 500 mg/kg. Body weights, food consumption and clinical signs were monitored daily; clinical pathology was conducted at designated intervals and animals were given a complete pathological evaluation after 12 months and 24 months of dosing. Normal survival was seen in all groups, no abnormal clinical signs were seen, and body weight gain was reduced only in female rats at 500 mg/kg. Both sexes at the high dose had mild decreases in red cell mass which were somewhat more pronounced in females. Clinical pathology indicative of liver injury was present in males that received 50 mg/kg and correlated with histomorphological liver changes that included both hypertrophic and degenerative/necrotic lesions. Similar histomorphological lesions were seen in the livers of females at 500 mg/kg. Previous shorter term toxicity studies have identified this chemical as a PPARα agonist and the finding of benign tumors of the liver, pancreas and/or testes in males at 50 mg/kg and females at 500 mg/kg is consistent with the rat response to peroxisome proliferators and is of questionable human relevance. Changes in the kidney, tongue, and stomach were observed only at the highest dose of 500 mg/kg in females. The no-observed-adverse-effect-level in this study lies between 1 and 50 mg/kg for males and between 50 and 500 mg/kg for females.

中文翻译：

---

2,3,3,3-四氟-2-（七氟丙氧基）-丙酸铵对Sprague–Dawley大鼠的慢性毒性和致癌性的评估

在为期2年的口服给药研究中，对2,3,3,3-四氟-2-（七氟丙氧基）-丙酸铵开发用于制造含氟聚合物的聚合加工助剂，对其潜在的慢性毒性和致癌性进行了测试。在Sprague–Dawley大鼠中。雄性大鼠每日服用0、0.1、1或50 mg / kg的剂量；雌性给予0、1、50或500 mg / kg。每天监测体重，食物消耗和临床体征；在指定的时间间隔进行临床病理检查，并在给药12个月和24个月后对动物进行完整的病理学评估。在所有组中均观察到正常存活，未观察到异常的临床体征，并且仅在500mg / kg的雌性大鼠中体重增加降低。高剂量的男女都具有轻微的红细胞减少，这在女性中更为明显。接受50 mg / kg男性治疗的临床病理表现为男性，并与包括肥大性和变性/坏死性病变在内的组织形态学肝脏变化相关。以500 mg / kg的剂量在雌性肝脏中观察到类似的组织形态学损害。先前的短期毒性研究已确定该化学物质为PPARα激动剂，在雄性50 mg / kg和雌性500 mg / kg中发现肝脏，胰腺和/或睾丸良性肿瘤与大鼠对过氧化物酶体的反应一致扩散者，与人类有关。仅在女性最高剂量为500 mg / kg时，才观察到肾脏，舌头和胃的变化。